Importantly, XIAP and cIAP2 were markedly induced in bone-marrow and lymph-node microenvironments, providing a basis for IAP antagonists as anti-tumor agents in CLL. This evidence concerns the gene BIRC3 and B-cell chronic lymphocytic leukemia.